Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefanie Hagenow

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Plos One|June 26, 2019
Ligand-guided homology modeling drives identification of novel histamine H3 receptor ligandsDavid Schaller, Stefanie Hagenow, Holger Stark, et al.
Bioorganic & Medicinal Chemistry|July 2, 2018
Design, synthesis, and biological evaluation of novel oxadiazole- and thiazole-based histamine H<sub>3</sub>R ligandsMohammad A Khanfar, David Reiner, Stefanie Hagenow, et al.
European Journal of Medicinal Chemistry|February 26, 2018
Novel indanone derivatives as MAO B/H<sub>3</sub>R dual-targeting ligands for treatment of Parkinson's diseaseAnna Affini, Stefanie Hagenow, Aleksandra Zivkovic, et al.
Bioorganic Chemistry|March 11, 2020
Isoquinoline alkaloids from the roots of Zanthoxylum rigidum as multi-target inhibitors of cholinesterase, monoamine oxidase A and Aβ<sub>1-42</sub> aggregationErika Plazas, Stefanie Hagenow, Monica Avila Murillo, et al.
Drug Design, Development and Therapy|February 27, 2020
Reversible Small Molecule Inhibitors of MAO A and MAO B with Anilide MotifsJens Hagenow, Stefanie Hagenow, Kathrin Grau, et al.
ACS Medicinal Chemistry Letters|June 20, 2017
Systematic Data Mining Reveals Synergistic H3R/MCHR1 LigandsDavid Schaller, Stefanie Hagenow, Gina Alpert, et al.
Molecules (Basel, Switzerland)|December 16, 2020
Parameters for Irreversible Inactivation of Monoamine OxidaseRona R Ramsay, Livia Basile, Antonin Maniquet, et al.
European Journal of Medicinal Chemistry|November 1, 2019
Search for new multi-target compounds against Alzheimer's disease among histamine H<sub>3</sub> receptor ligandsMarek Bajda, Dorota Łażewska, Justyna Godyń, et al.
Journal of Medicinal Chemistry|June 9, 2021
Adenosine A<sub>2A</sub>R/A<sub>1</sub>R Antagonists Enabling Additional H<sub>3</sub>R Antagonism for the Treatment of Parkinson's DiseaseStefanie Hagenow, Anna Affini, Elsa Y Pioli, et al.
Bioorganic & Medicinal Chemistry|November 19, 2018
Optimization and preclinical evaluation of novel histamine H<sub>3</sub>receptor ligands: Acetyl and propionyl phenoxyalkyl piperazine derivativesKatarzyna Szczepańska, Tadeusz Karcz, Magdalena Kotańska, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Plos One|June 26, 2019
Ligand-guided homology modeling drives identification of novel histamine H3 receptor ligandsDavid Schaller, Stefanie Hagenow, Holger Stark, et al.
Bioorganic & Medicinal Chemistry|July 2, 2018
Design, synthesis, and biological evaluation of novel oxadiazole- and thiazole-based histamine H<sub>3</sub>R ligandsMohammad A Khanfar, David Reiner, Stefanie Hagenow, et al.
European Journal of Medicinal Chemistry|February 26, 2018
Novel indanone derivatives as MAO B/H<sub>3</sub>R dual-targeting ligands for treatment of Parkinson's diseaseAnna Affini, Stefanie Hagenow, Aleksandra Zivkovic, et al.
Bioorganic Chemistry|March 11, 2020
Isoquinoline alkaloids from the roots of Zanthoxylum rigidum as multi-target inhibitors of cholinesterase, monoamine oxidase A and Aβ<sub>1-42</sub> aggregationErika Plazas, Stefanie Hagenow, Monica Avila Murillo, et al.
Drug Design, Development and Therapy|February 27, 2020
Reversible Small Molecule Inhibitors of MAO A and MAO B with Anilide MotifsJens Hagenow, Stefanie Hagenow, Kathrin Grau, et al.
ACS Medicinal Chemistry Letters|June 20, 2017
Systematic Data Mining Reveals Synergistic H3R/MCHR1 LigandsDavid Schaller, Stefanie Hagenow, Gina Alpert, et al.
Molecules (Basel, Switzerland)|December 16, 2020
Parameters for Irreversible Inactivation of Monoamine OxidaseRona R Ramsay, Livia Basile, Antonin Maniquet, et al.
European Journal of Medicinal Chemistry|November 1, 2019
Search for new multi-target compounds against Alzheimer's disease among histamine H<sub>3</sub> receptor ligandsMarek Bajda, Dorota Łażewska, Justyna Godyń, et al.
Journal of Medicinal Chemistry|June 9, 2021
Adenosine A<sub>2A</sub>R/A<sub>1</sub>R Antagonists Enabling Additional H<sub>3</sub>R Antagonism for the Treatment of Parkinson's DiseaseStefanie Hagenow, Anna Affini, Elsa Y Pioli, et al.
Bioorganic & Medicinal Chemistry|November 19, 2018
Optimization and preclinical evaluation of novel histamine H<sub>3</sub>receptor ligands: Acetyl and propionyl phenoxyalkyl piperazine derivativesKatarzyna Szczepańska, Tadeusz Karcz, Magdalena Kotańska, et al.
Pageof 2